Work Packages

The HEPAVAC Consortium will focus on the development of a novel and cutting-edge strategy for the generation of a peptide-based cancer vaccine approach for hepatocellular carcinoma patients, which will be evaluated in a European randomised, controlled, multi-centre Phase I/II human clinical trial. To assess this highly innovative approach, the HEPAVAC project will be divided into a “pre-clinical/translational” and a “clinical” phase.